CompanyBIIBNasdaqCambridge, MA

Biogen

Biogen discovers and develops therapies for multiple sclerosis, spinal muscular atrophy, Alzheimer's disease, amyotrophic lateral sclerosis, and Friedreich's ataxia.

Stories only

SEC EDGAR ClinicalTrials.gov biogen.com

424B5Sep 28Latest SEC filing

Sep 1Latest story

September 2026

Samsung Bioepis gets label supplement approved for Byooviz ranibizumab biosimilar

Sep 1Regulatory decisionBiogen Harrow Inc

July 2026

Biogen posts Q2 2026 results, sets five late-stage readouts over next four quarters

Jul 29Quarterly updateBiogen felzartamab

Biogen Phase 2 felzartamab trial in Graves' disease recruiting since July 2026

Jul 23Trial updateBiogen felzartamab

Moderna adds former Biogen CFO Michael McDonnell to board

Jul 8PeopleBiogen Moderna, Inc.

Biogen flags Q2 and Q3 2026 charges tied to licensing and milestone deals

Jul 1Quarterly updateBiogen

Pipeline by stage

Phase 3 primary completions, next 6 months

Oct 2026litifilimabchronic cutaneous lupus erythematosus · NCT05531565

Details

Headquarters: Cambridge, MA
Incorporated: Delaware
Industry: Biological Products, (No Diagnostic Substances)
Formerly: BIOGEN IDEC INC. (to 2015); BIOGEN IDEC INC (to 2007); IDEC PHARMACEUTICALS CORP / DE (to 2003); IDEC PHARMACEUTICALS CORP / CA (to 1997)
Also known as: BIIB, BIOGEN IDEC INC., BIOGEN INC., HI-Bio, and 5 more
Human Immunology Biosciences, IDEC PHARMACEUTICALS CORP / CA, IDEC PHARMACEUTICALS CORP / DE, Nightstar Therapeutics, Reata Pharmaceuticals

How the company describes itself

Biogen discovers and develops therapies for multiple sclerosis, spinal muscular atrophy, Alzheimer's disease, amyotrophic lateral sclerosis, and Friedreich's ataxia. The company markets multiple disease-modifying treatments for MS and approved therapies for SMA, ALS, FA, and Alzheimer's disease. source